Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 705 across all filing types
Latest filing 2024-03-30 Regulatory Filings
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the closure of the trading window pursuant to SEBI (Prohibition of Insider Trading) Regulations. It announces the trading window closure period related to the upcoming audited financial results for the quarter and year ended March 31, 2024. There is no actual financial data, report content, or detailed financial analysis included. The document is short (1229 characters) and serves as an announcement or notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related notices that do not fit other categories.
2024-03-30 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details an equity infusion by the parent company into its wholly-owned subsidiary via a rights issue, including specifics such as the amount, share price, percentage ownership, and background of the subsidiary. The document is addressed to stock exchanges and is a regulatory announcement about a capital transaction. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an update on a financing activity (equity infusion) and capital structure change. Therefore, it fits best under the category Capital/Financing Update (CAP). The document length is 4547 characters, which is sufficient for a detailed announcement but not a full report. Confidence is high given the clear regulatory reference and content focus on capital infusion.
2024-02-17 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) providing an update on the company's investment in another entity, specifically the payment of a tranche subscription amount and the resulting shareholding percentage. It references prior disclosures under SEBI (LODR) Regulations, indicating it is a regulatory update. The content is brief (1812 characters) and does not contain financial statements, detailed financial performance, or comprehensive report data. It is an announcement about a capital investment transaction update rather than a full capital/financing report or a detailed financial report. Given the nature of the update on investment and subscription payment, it fits best under Capital/Financing Update (CAP).
2024-02-17 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the schedule of analyst and institutional investor meetings. It references compliance with SEBI regulations and provides dates and details of upcoming investor conferences. There is no financial data, no detailed report, no voting results, no management changes, and no legal or capital structure updates. The document is an announcement of meetings rather than a report or transcript. Given its short length (1725 characters) and nature as an informational notice, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of the Q3 FY24 earnings conference call for Laurus Labs Limited held on January 24, 2024. It includes detailed management commentary on financial results, business updates, R&D progress, and outlook, as well as a Q&A session format typical of earnings calls. The text explicitly mentions it is a transcript of the earnings conference call and contains detailed financial and operational discussion for the quarter and nine months ended FY24. This matches the definition of a Call Transcript (CT). The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or summary, so it is not an Earnings Release (ER) or Report Publication Announcement (RPA). Therefore, the correct classification is Call Transcript (CT).
2024-01-30 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a joint venture agreement between Laurus Labs and Krka, Slovenia. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or strategic presentations. It is a corporate announcement about a business development (joint venture formation). The document is about a capital/business partnership agreement but does not discuss financing activities or capital structure changes in detail, so it is not a Capital/Financing Update (CAP). It is not a merger or acquisition filing (MA or TAR) since it is a joint venture announcement. The document is a press release, which is a public announcement of a corporate event. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-01-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.